1. Home
  2. YMM vs UTHR Comparison

YMM vs UTHR Comparison

Compare YMM & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YMM

Full Truck Alliance Co. Ltd. (each representing 20)

HOLD

Current Price

$11.51

Market Cap

12.3B

Sector

Technology

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$488.92

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YMM
UTHR
Founded
2011
1996
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3B
20.3B
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
YMM
UTHR
Price
$11.51
$488.92
Analyst Decision
Buy
Buy
Analyst Count
3
12
Target Price
$12.67
$495.08
AVG Volume (30 Days)
7.0M
424.3K
Earning Date
11-17-2025
10-29-2025
Dividend Yield
1.67%
N/A
EPS Growth
29.34
16.08
EPS
0.53
26.38
Revenue
$1,751,813,549.00
$3,128,400,000.00
Revenue This Year
$11.64
$13.64
Revenue Next Year
$8.97
$5.78
P/E Ratio
$21.94
$18.55
Revenue Growth
19.09
13.50
52 Week Low
$9.45
$266.98
52 Week High
$14.07
$492.62

Technical Indicators

Market Signals
Indicator
YMM
UTHR
Relative Strength Index (RSI) 47.00 68.10
Support Level $11.24 $470.13
Resistance Level $11.44 $492.62
Average True Range (ATR) 0.36 10.72
MACD 0.08 -0.53
Stochastic Oscillator 95.59 89.55

Price Performance

Historical Comparison
YMM
UTHR

About YMM Full Truck Alliance Co. Ltd. (each representing 20)

Full Truck Alliance Co Ltd, through its subsidiaries, provides comprehensive services for shippers and truckers through its mobile and website platforms. Its principal operations are in the People's Republic of China. The group derives its revenues principally from shippers and trucker's use of its platforms in connection with freight matching services and value-added services.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: